Home | Log in | Sitemap About Affibody Technology Partnering Investor Information News & Events Contact Research Reagents Research and development of protein-based therapeutics Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing. The company is currently developing four proprietary programs. The first three are therapeutic programs that targets prevention of Alzheimer’s disease, autoimmune diseases, and psoriasis respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody also has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, MedImmune, Nordic Nanovector, and Swedish Orphan Biovitrum. News 2016-08-19 Interim Report – January to June 2016 2016-05-20 Interim Report – January to March 2016 2016-05-04 Affibody Announces Initial Results from a Phase I Study of ABY-035 More news Events Archive Legal Notice

Start About Affibody Board of Directors Management Scientific Advisory Board Technical Advisory Board Technology Pipeline Partnering Partnering Opportunities Press & News 2016 2015 2014 2013 2012 2011 2010 2009 2008 Investor Annual Reports Interim Reports Presentations Financial Calendar Shareholder’s meetings Corporate Governance Contact Error 404 This page could not be found. Back to the home page Affibodys latest Press releases 2016-08-19 Interim Report – January to June 2016 Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based...[read more] News & Events Affibody in short Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. About Affibody Upcoming reports Financial calendar Q2 - Interim Report (August 19, 2016) Q3 interim report (November 18, 2016) Year-end report (February 24, 2017) Investor information Contact us Affibody Medical AB - Adress: Gunnar Asplunds Allé 24, SE-171 69 Solna, Sweden, E-post: reception@affibody.com, Tel: +46 (0)8 59 88 38 00 More contact information © 2016 Affibody Medical AB | All rights reserved Plucera Webbyrå